ScreenerHero

VTVTvTv Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · vtvtherapeutics.com
33.26USD+1.09%Mkt Cap: 131.49M $P/E: —

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap131.49M $
Enterprise Value324.36M $
Revenue (TTM)36.84M $
Gross Profit8.16M $
Net Income (TTM)-26.97M $
Revenue/Share3.250 USD
Last Price33.26 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees26
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.87
PEG—
EV/EBITDA-35.09
EV/Revenue8.80
P/S3.55
P/B5.22
EPS (TTM)-0.75
EPS (Forward)-4.21
52W Range
14.5564% of range44.00
52W High44.00 USD
52W Low14.55 USD
Profitability
Gross Margin22.16%
Oper. Margin-25.11%
EBITDA Margin-25.10%
Profit Margin-12.91%
ROE-41.86%
ROA-30.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.25M $
CapEx (TTM)—
FCF Margin1.83%
FCF Yield0.51%
Net Debt-86.64M $
Net Debt/EBITDA9.37
Balance Sheet
Debt/Equity0.00
Current Ratio12.48
Quick Ratio12.35
Book Value/Sh6.336 USD
Cash/Share6.974 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:40
Split DateNov 21, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)53.83 USD
Upside (mean)+61.9%
Target Range42.00 USD – 67.00 USD
$42.00+61.9% to mean$67.00
# Analysts6
Ownership
Shares Out.3.95M
Float2.16M
Insiders38.83%
Institutions40.75%
Short Interest
Short Ratio1.9d
Short % Float6.95%
Short % Out.4.21%
Shares Short165.79K
Short (prev mo.)163.68K
Technical
SMA 5033.16 (+0.3%)
SMA 20034.08 (-2.4%)
Beta0.29
S&P 52W Chg18.16%
Avg Vol (30d)92.73K
Avg Vol (10d)77.11K
Technical Indicators
RSI (14)52.6
MACD-0.2172
MACD Signal-0.2284
MACD Hist.+0.0111
BB Upper35.26 USD
BB Middle32.37 USD
BB Lower29.47 USD
BB Width17.89%
ATR (14)1.992 USD
Vol Ratio (20d)0.26x